![](/images/graphics-bg.png)
Silicone-Acyclovir Controlled Release Devices Suppress Primary Herpes Simplex Virus-2 and Varicella Zoster Virus Infections In Vitro
Joint Authors
Berkower, Carol L.
Johnson, Nicole M.
Margulies, Barry J.
Semenkow, Samantha L.
McGusty-Robinson, Shenika O.
Longdo, Stephen B.
Source
Advances in Pharmacological and Pharmaceutical Sciences
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-08-04
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Following initial infection, herpesviruses retreat into a permanent latent state with periodic reactivation resulting in an enhanced likelihood of transmission and clinical disease.
The nucleoside analogue acyclovir reduces clinical symptoms of the three human alpha herpesviruses, HSV-1, HSV-2, and VZV.
Long-term administration of acyclovir (ACV) can reduce the frequency and severity of reactivation, but its low bioavailability and short half-life require a daily drug regimen.
Our lab is working to develop a subcutaneous delivery system to provide long-lasting, sustained release of ACV.
Previously, we demonstrated that an implantable silicone (MED-4050) device, impregnated with ACV protected against HSV-1 both in vitro and in vivo.
Here, we extend our in vitro observations to include protection against both HSV-2 and VZV.
We also demonstrate protection against HSV-2 in vitro using MED-4750, a silicone polymer designed for long-term use in humans.
When release of ACV from MED-4750 is quantitated on a daily basis, an initial burst of 5 days is observed, followed by a long period of slow release with near-zero-order kinetics, with an average daily release of 1.3923 ± 0.5908 μg ACV over days 20–60.
Development of a slow-release implant has the potential to significantly impact the treatment of human alpha herpesvirus infections.
American Psychological Association (APA)
Berkower, Carol L.& Johnson, Nicole M.& Longdo, Stephen B.& McGusty-Robinson, Shenika O.& Semenkow, Samantha L.& Margulies, Barry J.. 2013. Silicone-Acyclovir Controlled Release Devices Suppress Primary Herpes Simplex Virus-2 and Varicella Zoster Virus Infections In Vitro. Advances in Pharmacological and Pharmaceutical Sciences،Vol. 2013, no. 2013, pp.1-9.
https://search.emarefa.net/detail/BIM-1003223
Modern Language Association (MLA)
Berkower, Carol L.…[et al.]. Silicone-Acyclovir Controlled Release Devices Suppress Primary Herpes Simplex Virus-2 and Varicella Zoster Virus Infections In Vitro. Advances in Pharmacological and Pharmaceutical Sciences No. 2013 (2013), pp.1-9.
https://search.emarefa.net/detail/BIM-1003223
American Medical Association (AMA)
Berkower, Carol L.& Johnson, Nicole M.& Longdo, Stephen B.& McGusty-Robinson, Shenika O.& Semenkow, Samantha L.& Margulies, Barry J.. Silicone-Acyclovir Controlled Release Devices Suppress Primary Herpes Simplex Virus-2 and Varicella Zoster Virus Infections In Vitro. Advances in Pharmacological and Pharmaceutical Sciences. 2013. Vol. 2013, no. 2013, pp.1-9.
https://search.emarefa.net/detail/BIM-1003223
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1003223